EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Astec LifeSciences Limited (ASTEC) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Astec LifeSciences Limited ₹110, price ₹709, upside -84.5%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Basic Materials · IN · ISIN INE563J01010

AL Thin data Sep 24, 2026

Astec LifeSciences Limited

ASTEC · NSE

Weakest SetupStrongly overvalued and low quality.

!Fair value ₹110.01 · Strongly overvalued (−84.5%)
!Quality 43/100
!Weak Growth (revenue 5y −4.2 %/yr)
!Loss-making · -18.1% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/9)
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain
Watch Astec LifeSciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹2,248 ₹521.85 Fair Value ₹110.01 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹521.85 – ₹2,248 · fair‑value band ₹82.09 – ₹164.19 · the ₹708.60 price screens above the ₹110.01 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Astec LifeSciences in your weekly email

Every Wednesday you see whether Astec LifeSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India.

Show more

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservatives. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited.

Stock analysis

Astec LifeSciences Limited (ASTEC) currently trades at ₹708.60, while our model-based Fair Value estimate is ₹110.01, 84.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: ₹82.09 (bear) to ₹164.19 (bull), the price of ₹708.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Astec LifeSciences Limited reported revenue of ₹4.5B in FY2026 versus ₹6.8B in FY2022, a compound −9.8%/yr. Reported net income was −₹809M in FY2026.

Key figures

Market cap ₹15.2B (≈ $158M) · P/S ratio 3.61 · EPS (TTM) ₹−37.80 · Net margin −18.1% · Return on equity −25.8% · Return on assets (EBIT) −0.8% · Operating margin −1.7% · Revenue (TTM) ₹4.5B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 23% below its 52-week high and 36% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 17% fair-value upside, at −84%, ASTEC screens richer than that median.

Fair Value models

Bear ₹82.09 Fair Value ₹110.01 Bull ₹164.19
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) ₹87.65 ₹117.45 ₹175.30 54
All 1 models by family
Asset-Based
NCAV (Graham) ₹87.65 ₹117.45 ₹175.30 54

Open the full fair value analysis →

Notify me when ASTEC reaches fair value

Put ASTEC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 41 · Market factors (momentum, volatility) 42

Profitability 7
Margins and returns on capital today
Quality Growth 89
Are margins and returns improving?
Cashflow 20
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 34
Distance to the 52-week high (market factor)
Net Issuance 26
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+17.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.2%
Start year 2021 (pandemic). Over 10 years: +5.6% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.7% (2021) → −11.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ASTEC screens overvalued: fair value 84% below the price. Compare with Corteva, Inc →

Compare Astec LifeSciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 177 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −84.5% · Bottom 25%
Profitability
Return on assets −3.4% · Bottom 25%
Net margin (TTM) −18.1% · Bottom 25%
Operating margin (TTM) −1.7% · Bottom 25%
Growth and dividend
Revenue growth 32.7% · Top 25%
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/S (TTM) 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 25
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Corteva, Inc CTVA $78.52 $28.63 −64%
Nutrien Ltd NTR $71.18 $83.09 +17%
Qinghai Salt Lake Industry Co 000792 ¥23.70 ¥26.81 +13%
CF Industries Holdings CF $115.51 $163.44 +41%
SABIC Agri-Nutrients Company 2020 123.60 SAR 150.65 SAR +22%
Yara International ASA YAR kr 433.10 kr 662.97 +53%
Yunnan Yuntianhua Co 600096 ¥27.56 ¥50.49 +83%
The Mosaic Company MOS $22.42 $25.77 +15%
ICL Group ICL $5.14 $2.98 −42%
Coromandel International Limited COROMANDEL ₹1,964 ₹1,129 −43%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Astec LifeSciences Limited · Fair Value
₹110.01 −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Astec LifeSciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/ASTEC

Frequently asked questions

Is Astec LifeSciences Limited (ASTEC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹110.01 versus a price of ₹708.60, about −84% upside (overvalued).
What is the fair value of ASTEC?
Our model-based fair value for Astec LifeSciences Limited is ₹110.01 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹708.60.
What is the quality score of ASTEC?
Astec LifeSciences Limited has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Astec LifeSciences Limited (ASTEC)?
Our model-based price target is the fair value of ₹110.01 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario ₹82.09, optimistic scenario ₹164.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Astec LifeSciences Limited stock forecast for 2026?
Our models put fair value at ₹110.01, about −84% upside versus a price of ₹708.60 (overvalued). Cautious scenario ₹82.09, optimistic scenario ₹164.19. The calculation is refreshed regularly with new filings.
What is the revenue of Astec LifeSciences Limited (ASTEC)?
Astec LifeSciences Limited reported trailing-twelve-month revenue of about ₹4.5B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Astec LifeSciences Limited (ASTEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Astec LifeSciences Limited it is ₹110.01 per share (as of Sep 24, 2026), against a price of ₹708.60. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Astec LifeSciences Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ASTEC trades above its calculated fair value: price ₹708.60, fair value ₹110.01, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASTEC?
No. The price is what the market pays today (₹708.60); the fair value is what the company's own numbers justify (₹110.01). For Astec LifeSciences Limited the two are ₹598.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Astec LifeSciences Limited worth?
The market values Astec LifeSciences Limited at about ₹15.2B (market capitalisation, as of Sep 24, 2026). Per share that is ₹708.60; our models calculate a fair value of ₹110.01 per share.
What do the bullish and bearish scenarios say about ASTEC?
Our models span a range for Astec LifeSciences Limited: cautious scenario ₹82.09, base ₹110.01, optimistic ₹164.19 per share (as of Sep 24, 2026, price ₹708.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Astec LifeSciences Limited (ASTEC)?
Balance-sheet figures for Astec LifeSciences Limited (as of Sep 24, 2026): return on equity −25.8%, debt of 0.13 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is ASTEC from its 52-week high?
Astec LifeSciences Limited trades at ₹708.60, about 23% below its 52-week high of ₹918.75 and 36% above the low of ₹521.85 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹110.01 is for.
Which stocks are comparable to Astec LifeSciences Limited?
From the same area (Basic Materials) we also value Corteva, Inc, Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Astec LifeSciences Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹708.60, calculated fair value ₹110.01 (−84%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASTEC calculated?
We run Astec LifeSciences Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹110.01, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Astec LifeSciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Astec LifeSciences Limited (ASTEC)?
The closing price on Oct 1, 2026 was ₹708.60. Our model-based fair value is ₹110.01, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Astec LifeSciences Limited right now?
The price sits above even our optimistic bull case (₹164.19). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹82.09 to ₹164.19) leaves room in how you read the outcome.

Key figures of Astec LifeSciences Limited

How large is the market capitalisation of Astec LifeSciences Limited (ASTEC)?
The market capitalisation of Astec LifeSciences Limited is ₹15.2B (≈ $158M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Astec LifeSciences Limited (ASTEC)?
The price-to-sales ratio of Astec LifeSciences Limited is 3.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Astec LifeSciences Limited (ASTEC)?
Earnings per share at Astec LifeSciences Limited are ₹−37.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Astec LifeSciences Limited (ASTEC)?
The net margin of Astec LifeSciences Limited is −18.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Astec LifeSciences Limited (ASTEC)?
The return on equity (ROE) of Astec LifeSciences Limited is −25.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Astec LifeSciences Limited (ASTEC)?
On an EBIT basis the return on assets of Astec LifeSciences Limited is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Astec LifeSciences Limited (ASTEC)?
The operating margin of Astec LifeSciences Limited is −1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Astec LifeSciences Limited (ASTEC)?
Revenue at Astec LifeSciences Limited is growing +32.7% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Astec LifeSciences Limited (ASTEC)?
Earnings per share at Astec LifeSciences Limited are growing −96.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Astec LifeSciences Limited (ASTEC) generate?
The free cash flow of Astec LifeSciences Limited is −₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Astec LifeSciences Limited (ASTEC) carry?
The net debt of Astec LifeSciences Limited is ₹4.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Astec LifeSciences Limited in the live analysis

One click puts Astec LifeSciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.